<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/10799A3B-C78B-4930-B3EA-AC72298BB624"><gtr:id>10799A3B-C78B-4930-B3EA-AC72298BB624</gtr:id><gtr:name>Medicines Patent Pool</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/AE58F21F-3622-4382-97BB-1359BD183E9F"><gtr:id>AE58F21F-3622-4382-97BB-1359BD183E9F</gtr:id><gtr:name>University of Glasgow</gtr:name><gtr:address><gtr:line1>University Avenue</gtr:line1><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G12 8QQ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/A0A585E0-6B0D-4643-A3A6-47943B4CBFEF"><gtr:id>A0A585E0-6B0D-4643-A3A6-47943B4CBFEF</gtr:id><gtr:name>University of Liverpool</gtr:name><gtr:department>Chemistry</gtr:department><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line2>Abercromby Square</gtr:line2><gtr:line4>Liverpool</gtr:line4><gtr:postCode>L69 3BX</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/A0A585E0-6B0D-4643-A3A6-47943B4CBFEF"><gtr:id>A0A585E0-6B0D-4643-A3A6-47943B4CBFEF</gtr:id><gtr:name>University of Liverpool</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line2>Abercromby Square</gtr:line2><gtr:line4>Liverpool</gtr:line4><gtr:postCode>L69 3BX</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/10799A3B-C78B-4930-B3EA-AC72298BB624"><gtr:id>10799A3B-C78B-4930-B3EA-AC72298BB624</gtr:id><gtr:name>Medicines Patent Pool</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/AE58F21F-3622-4382-97BB-1359BD183E9F"><gtr:id>AE58F21F-3622-4382-97BB-1359BD183E9F</gtr:id><gtr:name>University of Glasgow</gtr:name><gtr:address><gtr:line1>University Avenue</gtr:line1><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G12 8QQ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/71087E01-D085-4094-80C8-484FCF5B21D1"><gtr:id>71087E01-D085-4094-80C8-484FCF5B21D1</gtr:id><gtr:firstName>Kevin</gtr:firstName><gtr:surname>Park</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/11D1BC37-1FAE-4F3C-A479-74BD81C2B693"><gtr:id>11D1BC37-1FAE-4F3C-A479-74BD81C2B693</gtr:id><gtr:firstName>Andrew</gtr:firstName><gtr:surname>Cooper</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/EAF39237-6F9C-4169-A3F2-E1E730173D24"><gtr:id>EAF39237-6F9C-4169-A3F2-E1E730173D24</gtr:id><gtr:firstName>Saye</gtr:firstName><gtr:surname>Khoo</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/82CB5BD9-215B-45DE-9EB0-07E1554FB31F"><gtr:id>82CB5BD9-215B-45DE-9EB0-07E1554FB31F</gtr:id><gtr:firstName>Andrew</gtr:firstName><gtr:surname>Owen</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/77F021F2-CB59-421B-9A71-664FE2218FBD"><gtr:id>77F021F2-CB59-421B-9A71-664FE2218FBD</gtr:id><gtr:firstName>Munir</gtr:firstName><gtr:surname>Pirmohamed</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/DD82B8F7-2993-462C-B5B3-2A50A0CCA662"><gtr:id>DD82B8F7-2993-462C-B5B3-2A50A0CCA662</gtr:id><gtr:firstName>Steven</gtr:firstName><gtr:surname>Rannard</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/C7FD0EB4-CDA8-4E45-BBE0-574583CB57C1"><gtr:id>C7FD0EB4-CDA8-4E45-BBE0-574583CB57C1</gtr:id><gtr:firstName>Adam Jan</gtr:firstName><gtr:surname>Kowalski</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=EP%2FG066272%2F1"><gtr:id>B1CB0F16-E66F-4B9E-A4C5-4DB50DAC8BAC</gtr:id><gtr:title>Non-Attrition HAART nanoparticle therapies for HIV/AIDS Drug Delivery</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>EP/G066272/1</gtr:grantReference><gtr:abstractText>New nanomedicine approaches are being developed to significantly enhance HIV/AIDS treatments. The medicines will be aimed at targeting the virus in areas that are very diffcult for conventional drugs to reach. The work builds on previous success at the University of Liverpool and has a plan to fully engage with the public.</gtr:abstractText><gtr:fund><gtr:end>2012-10-30</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/798CB33D-C79E-4578-83F2-72606407192C"><gtr:id>798CB33D-C79E-4578-83F2-72606407192C</gtr:id><gtr:name>EPSRC</gtr:name></gtr:funder><gtr:start>2009-05-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>1392994</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medicines Patent Pool</gtr:collaboratingOrganisation><gtr:country>Switzerland, Swiss Confederation</gtr:country><gtr:description>Medicines Patent Pool</gtr:description><gtr:id>D944BA7A-6125-46C1-AF76-DD6C34BD5882</gtr:id><gtr:impact>None as yet</gtr:impact><gtr:partnerContribution>MPP are seeking partners for scale up and translation of clinical outputs to enable therapy scale up and charitable access</gtr:partnerContribution><gtr:piContribution>Development of prototype and clinical candidate therapies (nanomedicine) for HIV treatment</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Glasgow</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>English Language</gtr:department><gtr:description>EU Nanocharacterisation Laboratory</gtr:description><gtr:id>B581FF1F-EBFD-4144-9EF4-3BEFEAA9FF10</gtr:id><gtr:impact>No outputs as yet</gtr:impact><gtr:partnerContribution>Additional input from multiple EU partners to characterise candidate nanomedicines</gtr:partnerContribution><gtr:piContribution>The University of Liverpool team provide critical expertise developed through EPSRC grant funded activity, to the Horizon 2020 funded European Nanocharcterisation Laboratory</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Liverpool Life Sciences Network Spring Networking Event</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>6EB2FB55-931E-4B67-8754-3C41C990CD04</gtr:id><gtr:impact>Presentation and discussion with schoolchildren on Nanomedicine.

Held as part of the International Society on Thrombosis and Haemostasis (ISTH) conference, BT Convention Centre, Liverpool, UK 2012</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Schools Outreach activity</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>3393A27C-5F28-4D99-886E-45E231A462B9</gtr:id><gtr:impact>Vardean College/RSC Sixth former science meeting. Engagement with 6th formers to explain current progress in Nanomedicine</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Princes Teaching Institute CPD</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>69300B6C-EB22-4FB3-BE0C-18F170D80E6E</gtr:id><gtr:impact>CPD for teachers. Presentation designed to update teachers with up to date information to allow teaching knowledge in Nanomedicine</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Meeting to discuss research outputs with Global Charity (Clinton Health Access Initiative)</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>AE61CF6B-8CCD-4BBE-B758-91EC5282ABBD</gtr:id><gtr:impact>Activity was used to engage with the Clinton Health Access Initiative to receive support and garner interest in translational activities directed at candidate global HIV nanomedicine therapy development</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Third sector organisations</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Meeting with industry (Revolymer)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>99D8095F-A2FC-4738-A35F-A62AD2D1861A</gtr:id><gtr:impact>Engagement with research activities and future licence/collaborative research opportunities</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Industry/Business</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Meeting with Industry (AZ)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>DB682677-6531-4ACE-ABBB-A54F29D905A5</gtr:id><gtr:impact>Significant interest in nanomedicine activities. Event allowed detailed engagement in discussion to evaluate future collaboration activities</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Industry/Business</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Website for the British Society for Nanomedicine</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>86833B86-31EF-4F77-A341-CB845EA05070</gtr:id><gtr:impact>As part of the creation and launch of the British Society for Nanomedicine as website has been created allowing access to information for children, schools, the public and scientists (academic and industrial)

The Society now has &amp;gt;300 members globally and has held multiple meetings</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Meetings with Medicines Patent Pool (Geneva)</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>8AD9170F-A31C-40D8-8C8B-4D672A47C072</gtr:id><gtr:impact>Discussions to evaluate licence opportunities to allow translation of research outputs through charitable funding and generic pharma companies. MPP are UNITAID funded</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Third sector organisations</gtr:primaryAudience><gtr:year>2014,2015</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>5000000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:description>USAID PEPFAR ART Simplification</gtr:description><gtr:end>2020-09-02</gtr:end><gtr:fundingOrg>USAID</gtr:fundingOrg><gtr:fundingRef>AID-OAA-A-15-00069</gtr:fundingRef><gtr:id>C7358A03-A678-4CAD-8C87-B7ED5BB0BF91</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2015-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>914582</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Funding for Imaging</gtr:description><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MR/K015931/1</gtr:fundingRef><gtr:id>0940C385-8BB0-40A3-BF6A-49ED678F4E73</gtr:id><gtr:sector>Academic/University</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>349000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Industrial Funding - Agrochemicals</gtr:description><gtr:end>2017-12-02</gtr:end><gtr:fundingOrg>Industry Partners</gtr:fundingOrg><gtr:id>B167F000-158E-43DB-8E9F-AB230EEF9CA4</gtr:id><gtr:sector>Private</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1210035</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:description>US NIH R01 funding</gtr:description><gtr:fundingOrg>National Institutes of Health (NIH)</gtr:fundingOrg><gtr:fundingRef>R01AI114405</gtr:fundingRef><gtr:id>85EF87CB-6941-4DDA-AE9D-33F649C28B10</gtr:id><gtr:sector>Public</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1333141</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Towards NanoMedicine Interventions for HIV/AIDS</gtr:description><gtr:fundingOrg>Engineering and Physical Sciences Research Council (EPSRC)</gtr:fundingOrg><gtr:fundingRef>EP/K002201/1</gtr:fundingRef><gtr:id>35487C4D-A832-4CED-8687-E3B818D2AF00</gtr:id><gtr:sector>Academic/University</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>99583</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>British Society for Antimicrobial Chemot</gtr:description><gtr:fundingOrg>British Society for Antimicrobial Chemotherapy</gtr:fundingOrg><gtr:id>84438E2A-2DC7-452C-8F85-F00FB7F26170</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>87922</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>NIH Funding from US</gtr:description><gtr:end>2014-09-02</gtr:end><gtr:fundingOrg>National Institutes of Health (NIH)</gtr:fundingOrg><gtr:id>15558CFA-7F99-4A37-9B66-70EC04B650FE</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2013-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>829000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Industrial Funding</gtr:description><gtr:end>2019-04-02</gtr:end><gtr:fundingOrg>Industry Partners</gtr:fundingOrg><gtr:id>E0B917D7-88EE-4EB7-B651-9C00F07D3A09</gtr:id><gtr:sector>Private</gtr:sector><gtr:start>2017-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>87922</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>NIH Funding from US</gtr:description><gtr:fundingOrg>National Institutes of Health (NIH)</gtr:fundingOrg><gtr:id>4440C7DD-5309-4433-B83F-2FEF4FE492D4</gtr:id><gtr:sector>Public</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>890496</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>New Nanoscale Drug Delivery Systems and their Application to HIV/AIDS treatment</gtr:description><gtr:end>2015-10-02</gtr:end><gtr:fundingOrg>Engineering and Physical Sciences Research Council (EPSRC)</gtr:fundingOrg><gtr:fundingRef>EP/I038721/1</gtr:fundingRef><gtr:id>3A5DC9AD-3F0D-4FD8-B408-58DD816208A4</gtr:id><gtr:sector>Academic/University</gtr:sector></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs><gtr:impactSummaryOutput><gtr:description>The outputs of the work were progressed through a follow-on EPSRC grant and have led to healthy volunteer studies (human trials) of the world's first orally dosed nanomedicine for HIV. This data has led to another first - the academic technology provider agreement with the UNITAID-funded Medicines Patent Pool - and engagement with &amp;gt;20 potential industry development partners. USAID have also included Liverpool as a fundamental science collaborator within a $50m (US) international consortium to enable further nanomedicine development.

New national society to engage with academic, industry and the general public.

A new society, the British Society for Nanomedicine, has been launched to engage the public, industry and academics in nanomedicine throughout the UK. The site offers updates of ongoing research, classroom activities for schools, a members forum, conference listings and translation of published research to lay summaries for public/non-specialist reading.

Beneficiaries: Public, industry and academics

Contribution Method: The society is a forum for skilled and untrained people to engage with UK nanomedicine research. The launch event involved researchers from the UK, US and EU and patient groups. Trustees are drawn from clinical, chemical, toxicological and pharmacological research backgrounds.</gtr:description><gtr:firstYearOfImpact>2015</gtr:firstYearOfImpact><gtr:id>A78E5A2C-5B7A-405A-B853-FFC083B7CF91</gtr:id><gtr:impactTypes><gtr:impactType>Cultural,Societal</gtr:impactType></gtr:impactTypes><gtr:sector>Healthcare,Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:impactSummaryOutput></gtr:impactSummaryOutputs><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>The present inventions relates to a solid composition and an aqueous dispersion comprising nanoparticles of the anti-retroviral drug efavirenz. The solid composition and aqueous dispersion additionally comprise a mixture of a hydrophilic polymer and a surfactant. The surfactant is selected from vitamin-E-polyethylene glycol-succinate (Vit- E-PEG-succinate), a polyoxyethylene sorbitan fatty acid ester, N-alkyldimethylbenzylammonium chloride, sodium deoxycholate, dioctyl sodium sulfosuccinate, polyethyleneglycol-12-hydroxystearate, polyvinyl alcohol (PVA), and a block copolymer of polyoxyethylene and polyoxypropylene, or a combination thereof. The hydrophilic polymer is suitably selected from polyvinyl alcohol (PVA), a polyvinyl alcohol-polyethylene glycol graft copolymer, a block copolymer of polyoxyethylene and polyoxypropylene, polyethylene glycol, hydroxypropyl methyl cellulose (HPMC), and polyvinylpyrrolidone, or a combination thereof. The present invention also relates to processes for preparing both the solid composition and the aqueous dispersion, as well as to their use in therapy for the treatment and/or prevention of retroviral infections such as human immunodeficiency virus (HIV).</gtr:description><gtr:id>7748ABE6-0D6E-4D78-A7D9-38013AA5A7D9</gtr:id><gtr:impact>Supporting human clinical trials</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:patentId>WO2013034925</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>COMPOSITIONS OF EFAVIRENZ</gtr:title><gtr:yearProtectionGranted>2013</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>The present inventions relates to a solid composition and an aqueous dispersion comprising nanoparticles of the anti-retroviral drug efavirenz. The solid composition and aqueous dispersion additionally comprise a mixture of a hydrophilic polymer and a surfactant. The surfactant is selected from vitamin-E-polyethylene glycol-succinate (Vit- E-PEG-succinate), a polyoxyethylene sorbitan fatty acid ester, N-alkyldimethylbenzylammonium chloride, sodium deoxycholate, dioctyl sodium sulfosuccinate, polyethyleneglycol-12-hydroxystearate, polyvinyl alcohol (PVA), and a block copolymer of polyoxyethylene and polyoxypropylene, or a combination thereof. The hydrophilic polymer is suitably selected from polyvinyl alcohol (PVA), a polyvinyl alcohol-polyethylene glycol graft copolymer, a block copolymer of polyoxyethylene and polyoxypropylene, polyethylene glycol, hydroxypropyl methyl cellulose (HPMC), and polyvinylpyrrolidone, or a combination thereof. The present invention also relates to processes for preparing both the solid composition and the aqueous dispersion, as well as to their use in therapy for the treatment and/or prevention of retroviral infections such as human immunodeficiency virus (HIV).</gtr:description><gtr:id>ECA07F45-122F-47C3-8CB9-42976A88D88B</gtr:id><gtr:impact>The patent is supporting a human clinical trial and has initiated interest from global charities and the NIH (US)</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:patentId>WO2013034925</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>COMPOSITIONS OF EFAVIRENZ</gtr:title><gtr:yearProtectionGranted>2013</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>The present inventions relates to a solid composition and an aqueous dispersion comprising nanoparticles of the anti-retroviral drugs lopinavir and ritonavir. The solid composition and aqueous dispersion additionally comprise a mixture of a hydrophilic polymer and a surfactant. The surfactant is selected from vitamin-E-polyethylene glycol- succinate (Vit-E-PEG-succinate), a polyoxyethylene sorbitan fatty acid ester, N- alkyldimethylbenzylammonium chloride, sodium deoxycholate, dioctyl sodium sulfosuccinate, polyethyleneglycol-12-hydroxystearate, polyvinyl alcohol (PVA), and a block copolymer of polyoxyethylene and polyoxypropylene, or a combination thereof. The hydrophilic polymer is suitably selected from polyvinyl alcohol (PVA), a polyvinyl alcohol-polyethylene glycol graft copolymer, a block copolymer of polyoxyethylene and polyoxypropylene, polyethylene glycol, hydroxypropyl methyl cellulose (HPMC), and polyvinylpyrrolidone, or a combination thereof. The present invention also relates to processes for preparing both the solid composition and the aqueous dispersion, as well as to their use in therapy for the treatment and/or prevention of retroviral infections such as human immunodeficiency virus (HIV).</gtr:description><gtr:id>55336DC0-4FF3-471F-90E9-EDD6AE6F760F</gtr:id><gtr:impact>Currently supporting human clinical trials</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:patentId>WO2013034927</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>COMPOSITIONS OF LOPINAVIR AND RITONAVIR</gtr:title><gtr:yearProtectionGranted>2011</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>The present invention relates to a solid composition and an aqueous dispersion comprising nanoparticles of the anti-retroviral drug lopinavir. The solid composition and aqueous dispersion additionally comprise a mixture of a hydrophilic polymer and a surfactant. The surfactant is selected from vitamin-E-polyethylene glycol-succinate (Vit- E-PEG-succinate), a polyoxyethylene sorbitan fatty acid ester, N- alkyldimethylbenzylammonium chloride, sodium deoxycholate, dioctyl sodium sulfosuccinate, polyethyleneglycol-12-hydroxystearate, polyvinyl alcohol (PVA), and a block copolymer of polyoxyethylene and polyoxypropylene, or a combination thereof. The hydrophilic polymer is suitably selected from polyvinyl alcohol (PVA), a polyvinyl alcohol-polyethylene glycol graft copolymer, a block copolymer of polyoxyethylene and polyoxypropylene, polyethylene glycol, hydroxypropyl methyl cellulose (HPMC), and polyvinylpyrrolidone, or a combination thereof. The present invention also relates to processes for preparing both the solid composition and the aqueous dispersion, as well as to their use in therapy for the treatment and/or prevention of retroviral infections such as human immunodeficiency virus (HIV).</gtr:description><gtr:id>42ECB523-1422-4D60-81B9-8708511C7EDF</gtr:id><gtr:impact>This patent is underpinning a human clinical trial and has attracted considerable global interest from charities and NIH (US)</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:patentId>WO2013034926</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>COMPOSITIONS OF LOPINAVIR</gtr:title><gtr:yearProtectionGranted>2013</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>The present invention relates to a porous composite material comprising a hydrophilic carrier carrying a magnetic material. The porous composite material can include a hydrophobic polymer, hydrophobic material, organic compound, and/or pharmaceutically active ingredient. The porous composite material is prepared by a modified emulsion templating and freeze-drying procedure. Magnetic nanoparticles are released from the porous composite material on application of water.</gtr:description><gtr:id>252C7AC1-B737-45B3-8B1B-885B0F755204</gtr:id><gtr:impact>The patent application was marketed and latterly allowed to lapse</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:patentId>WO2012143733</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>NANOPARTICLES</gtr:title><gtr:yearProtectionGranted>2012</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>The present inventions relates to a solid compn. and an aq. dispersion comprising nanoparticles of the antiretroviral drugs lopinavir and ritonavir. The solid compn. and aq. dispersion addnl. comprise a mixt. of a hydrophilic polymer and a surfactant. The surfactant is selected from vitamin-E-polyethylene glycol succinate (Vit-E-PEG-succinate), a polyoxyethylene sorbitan fatty acid ester, N-alkyldimethylbenzylammonium chloride, sodium deoxycholate, dioctyl sodium sulfosuccinate, polyethyleneglycol 12-hydroxystearate, polyvinyl alc., and a block copolymer of polyoxyethylene and polyoxypropylene, or a combination thereof. The hydrophilic polymer is suitably selected from polyvinyl alc. (PVA), a polyvinyl alc.-polyethylene glycol graft copolymer, a block copolymer of polyoxyethylene and polyoxypropylene, polyethylene glycol, hydroxypropyl Me cellulose (HPMC), and polyvinylpyrrolidone, or a combination thereof. The present invention also relates to processes for prepg. both the solid compn. and the aq. dispersion, as well as to their use in therapy for the treatment and/or prevention of retroviral infections such as human immunodeficiency virus (HIV).</gtr:description><gtr:id>15584272-36DC-4EBA-96A7-5F1AEFA9EE72</gtr:id><gtr:impact>Much interest in this patent application as part of a larger portfolio and negotiations to progress to human trials are ongoing</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:patentId>WO2013034927</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>COMPOSITIONS OF LOPINAVIR AND RITONAVIR</gtr:title><gtr:yearProtectionGranted>2014</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>The present invention relates to a solid composition and an aqueous dispersion comprising nanoparticles of the anti-retroviral drug lopinavir. The solid composition and aqueous dispersion additionally comprise a mixture of a hydrophilic polymer and a surfactant. The surfactant is selected from vitamin-E-polyethylene glycol-succinate (Vit- E-PEG-succinate), a polyoxyethylene sorbitan fatty acid ester, N- alkyldimethylbenzylammonium chloride, sodium deoxycholate, dioctyl sodium sulfosuccinate, polyethyleneglycol-12-hydroxystearate, polyvinyl alcohol (PVA), and a block copolymer of polyoxyethylene and polyoxypropylene, or a combination thereof. The hydrophilic polymer is suitably selected from polyvinyl alcohol (PVA), a polyvinyl alcohol-polyethylene glycol graft copolymer, a block copolymer of polyoxyethylene and polyoxypropylene, polyethylene glycol, hydroxypropyl methyl cellulose (HPMC), and polyvinylpyrrolidone, or a combination thereof. The present invention also relates to processes for preparing both the solid composition and the aqueous dispersion, as well as to their use in therapy for the treatment and/or prevention of retroviral infections such as human immunodeficiency virus (HIV).</gtr:description><gtr:id>77C95FDD-EBBE-4FBA-9268-D99CF4808D35</gtr:id><gtr:impact>Currently supporting human clinical trials</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:patentId>WO2013034926</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>COMPOSITIONS OF LOPINAVIR</gtr:title><gtr:yearProtectionGranted>2013</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:keyFindingsOutput><gtr:description>The project aimed to study the potential benefits of generating nanoparticles of antiretroviral medicines, used in the treatment of HIV/AIDS, to enhance the treatment outcomes for patients globally. For the three antiretrovirals that were studied, nanoparticle dispersions were considerably less cytotoxic, a significant population of the nanodispersions accumulated higher in target cell types and a large population were shown to transport through the gut higher than conventional formulations. The implications are that lower doses are potentially possible, with reduced toxicity profiles and a higher potential for patients to maintain adherence to their prescriptions. Penetration into target tissues and cells were also enhanced and so was antiretroviral activity. The materials also showed no specific immunological issues. In summary, the world's first potential oral nanomedicines for HIV sufferers was created during the programme, leading to considerable potential for global impact.</gtr:description><gtr:exploitationPathways>The exploitation is being directed through charitable end-users who are targeting patients in resource-poor countries where HIV is highly prevalent (in some cases as high as 30% of the adult population). Commercial partners are also keen to launch new HIV/AIDS therapies using current drugs but with benefits such as reduced dose, reduced toxicity and enhanced patient compliance. The outcomes of the project have been patented to enable industrial translation and progression through to actual patient benefits. Considerable interest has been generated within the clinical research arena and charitable organisations (Medecins Sans Frontiere, Drugs for Neglected Diseases initiative) for nanomedicine development in both the developed and developing world. Considerable additional funding has been awarded to progress to human trials that will hopefully demonstrate the value in early stage bioavailability studies. Success here will see rapid take-up both charitably and commercially through current partners.</gtr:exploitationPathways><gtr:id>CE95963E-D8CC-4D2F-AFC8-46AEEE97BEBD</gtr:id><gtr:sectors><gtr:sector>Chemicals,Healthcare,Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:sectors><gtr:url>http://www.azonano.com/news.aspx?newsID=34190%20</gtr:url></gtr:keyFindingsOutput><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Membership of Innovate UK Emerging Technologies and Industries Steering Committee</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>23337462-22A8-4CA4-A28F-D98E1197530A</gtr:id><gtr:type>Membership of a guideline committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>Human study of pharmacokinetics of orally dosed nanoparticles of efavirenz aiming at dose and pill burden reduction. Engagement with international charities (Clinton Health Access Initiative; Medicines Patent Pool, MSF) and further funding from NIH (collaboration with Johns Hopkins Medical School) and USAID (Multinational collaboration) to establish potential in other HIV related areas and malarial opportunities.</gtr:description><gtr:id>F1046B4F-F3A1-4F33-B41C-57E79E93B9E3</gtr:id><gtr:impact>Awaiting outcomes</gtr:impact><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Actively seeking support</gtr:status><gtr:title>Human trial of candidate nanomedicine for HIV using Efavirenz</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2016</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>This is an nanomedicine for HIV therapy aiming to dramatically reduce the dose and the overall pill burden for HIV sufferers. There is also potential for paediatric therapy development.</gtr:description><gtr:id>BD92776C-AF7A-494E-AA19-86E10FD5B9D4</gtr:id><gtr:impact>Licence agreement signed with UNITAID-funded Medicines Patent Pool (Geneva) and considerable additional funding to establish potential within other drugs for HIV (USAID multinational collaboration) and malaria (interatction with Johns Hopkins Medical School). In addition, significant engagement with Clinton Health Access Initiative and the securing of an R01 grant from NIH to study long acting HIV nanomedicines with a team from Johns Hopkins Medical School.</gtr:impact><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Actively seeking support</gtr:status><gtr:title>Oral Nanomedicine for HIV using Lopinavir</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2016</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs><gtr:spinOutOutput><gtr:companyName>Tandem Nano Ltd</gtr:companyName><gtr:description>Tandem Nano Ltd is a nanoformulation company aiming to improve the action, delievry, use and behaviour of poorly soluble compounds</gtr:description><gtr:id>EAE5AE9E-70DA-42AE-AD2F-C30BC1B3898D</gtr:id><gtr:impact>Currently negotiating meaningful interactions with numerous global companies</gtr:impact><gtr:url>http://www.tandemnano.com/</gtr:url><gtr:yearCompanyFormed>2014</gtr:yearCompanyFormed></gtr:spinOutOutput></gtr:spinOutOutputs></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E6965F87-9B0A-4127-966C-F79A2F891848"><gtr:id>E6965F87-9B0A-4127-966C-F79A2F891848</gtr:id><gtr:title>In vitro characterization of efavirenz-containing solid drug nanoparticles</gtr:title><gtr:parentPublicationTitle>ANTIVIRAL THERAPY</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/151899c7dd6c7ddeaac6bd47d81d2efa"><gtr:id>151899c7dd6c7ddeaac6bd47d81d2efa</gtr:id><gtr:otherNames>King S. C.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1359-6535</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/55D3E95F-5415-4FE8-89F5-B986ADA9C160"><gtr:id>55D3E95F-5415-4FE8-89F5-B986ADA9C160</gtr:id><gtr:title>Considerations for clinically-relevant nanomedicine therapies for chronic diseases.</gtr:title><gtr:parentPublicationTitle>Nanomedicine (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/cf1d6d619c42388d8cdb238501bb7319"><gtr:id>cf1d6d619c42388d8cdb238501bb7319</gtr:id><gtr:otherNames>Owen A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1743-5889</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/FA2B7F90-DB10-4023-A7F4-C4FDF01444CE"><gtr:id>FA2B7F90-DB10-4023-A7F4-C4FDF01444CE</gtr:id><gtr:title>INVITED ELRIG Meeting at AstraZeneca</gtr:title><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/41bbb57a2c373192de3711a2c22e3062"><gtr:id>41bbb57a2c373192de3711a2c22e3062</gtr:id><gtr:otherNames>Steven Rannard (Author)</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C90FDCCB-0C77-4F9A-9B1E-9C738F6E5F47"><gtr:id>C90FDCCB-0C77-4F9A-9B1E-9C738F6E5F47</gtr:id><gtr:title>4th Annual Georgia Nanotechnology and Infectious Disease Symposium</gtr:title><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/5f1d0b33a9155ad878eeb3bfd94192bb"><gtr:id>5f1d0b33a9155ad878eeb3bfd94192bb</gtr:id><gtr:otherNames>Steve  Rannard (Author)</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/789D32A3-CF9D-4205-98B1-5336E345B5B7"><gtr:id>789D32A3-CF9D-4205-98B1-5336E345B5B7</gtr:id><gtr:title>Mediation of in vitro cytochrome p450 activity by common pharmaceutical excipients.</gtr:title><gtr:parentPublicationTitle>Molecular pharmaceutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/8aebd9fcdb75ba6a10430e6f39a62dd8"><gtr:id>8aebd9fcdb75ba6a10430e6f39a62dd8</gtr:id><gtr:otherNames>Martin P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1543-8384</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C8B13BD1-0833-444E-A21B-5D6910868744"><gtr:id>C8B13BD1-0833-444E-A21B-5D6910868744</gtr:id><gtr:title>Nanoformulation strategies for the enhanced oral bioavailability of antiretroviral therapeutics.</gtr:title><gtr:parentPublicationTitle>Therapeutic delivery</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/aba5e9bae9a56a3e6b33f6cf48ec89fa"><gtr:id>aba5e9bae9a56a3e6b33f6cf48ec89fa</gtr:id><gtr:otherNames>Tatham LM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2041-5990</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/EDF45905-D0DE-44D0-A808-AB093A0661AD"><gtr:id>EDF45905-D0DE-44D0-A808-AB093A0661AD</gtr:id><gtr:title>INVITED British Toxicology Society Meeting</gtr:title><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/379c8a6500a97b873ca17b2dc0a64cf2"><gtr:id>379c8a6500a97b873ca17b2dc0a64cf2</gtr:id><gtr:otherNames>Andrew Owen (Author)</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/192C7CED-22DA-4D00-A36C-8CFB03F3FE22"><gtr:id>192C7CED-22DA-4D00-A36C-8CFB03F3FE22</gtr:id><gtr:title>POLY 529-Water-dispersible organic nanoparticles by freeze drying</gtr:title><gtr:parentPublicationTitle>ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/edf9cce415f1259ec0078ac2ebeeffad"><gtr:id>edf9cce415f1259ec0078ac2ebeeffad</gtr:id><gtr:otherNames>Zhang Haifei</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0065-7727</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/CB8EEE65-D9E9-4D31-A6DF-6469F7A4927B"><gtr:id>CB8EEE65-D9E9-4D31-A6DF-6469F7A4927B</gtr:id><gtr:title>Flow cytometric analysis of the physical and protein-binding characteristics of solid drug nanoparticle suspensions.</gtr:title><gtr:parentPublicationTitle>Nanomedicine (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/936be8fe289660558eed2b8dc4f61ee3"><gtr:id>936be8fe289660558eed2b8dc4f61ee3</gtr:id><gtr:otherNames>Liptrott NJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1743-5889</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/FABDBDE5-5318-433C-BA0D-6E7B6327D9A0"><gtr:id>FABDBDE5-5318-433C-BA0D-6E7B6327D9A0</gtr:id><gtr:title>Nanomedicines for HIV therapy.</gtr:title><gtr:parentPublicationTitle>Therapeutic delivery</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/65da67b16bc5ccd9ce1b330b734b99ed"><gtr:id>65da67b16bc5ccd9ce1b330b734b99ed</gtr:id><gtr:otherNames>Siccardi M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2041-5990</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/17965347-447D-4896-BC6A-56A36C60C253"><gtr:id>17965347-447D-4896-BC6A-56A36C60C253</gtr:id><gtr:title>12th International Workshop on Clinical Pharmacology of HIV Therapy</gtr:title><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/91e7fdbac79e2e16955c5bf004c271a8"><gtr:id>91e7fdbac79e2e16955c5bf004c271a8</gtr:id><gtr:otherNames>Andrew  Owen (Author)</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/27A7ABFD-9976-4DBC-94F8-40FE76AE9959"><gtr:id>27A7ABFD-9976-4DBC-94F8-40FE76AE9959</gtr:id><gtr:title>Inaugural Meeting of the British Society for Nanomedicine</gtr:title><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/91e7fdbac79e2e16955c5bf004c271a8"><gtr:id>91e7fdbac79e2e16955c5bf004c271a8</gtr:id><gtr:otherNames>Andrew  Owen (Author)</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/42359520-D28F-4B50-802E-F39A52E40755"><gtr:id>42359520-D28F-4B50-802E-F39A52E40755</gtr:id><gtr:title>Facile synthesis of complex multi-component organic and organic-magnetic inorganic nanocomposite particles</gtr:title><gtr:parentPublicationTitle>Journal of Materials Chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/236f8fefb1de42b371cef64a9fd83257"><gtr:id>236f8fefb1de42b371cef64a9fd83257</gtr:id><gtr:otherNames>Giardiello M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/829AEA27-C12B-45A4-8121-3E6C3BD18167"><gtr:id>829AEA27-C12B-45A4-8121-3E6C3BD18167</gtr:id><gtr:title>Antiretroviral solid drug nanoparticles with enhanced oral bioavailability: production, characterization, and in vitro-in vivo correlation.</gtr:title><gtr:parentPublicationTitle>Advanced healthcare materials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/0417a44a7ef591b40114351d26ff40bb"><gtr:id>0417a44a7ef591b40114351d26ff40bb</gtr:id><gtr:otherNames>McDonald TO</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2192-2640</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/5CBA3274-DF56-4904-A7DE-4EAEB6AB5259"><gtr:id>5CBA3274-DF56-4904-A7DE-4EAEB6AB5259</gtr:id><gtr:title>Use of a physiologically-based pharmacokinetic model to simulate artemether dose adjustment for overcoming the drug-drug interaction with efavirenz.</gtr:title><gtr:parentPublicationTitle>In silico pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/65da67b16bc5ccd9ce1b330b734b99ed"><gtr:id>65da67b16bc5ccd9ce1b330b734b99ed</gtr:id><gtr:otherNames>Siccardi M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2193-9616</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/15F1E453-DB65-48F9-8084-D011C03644F6"><gtr:id>15F1E453-DB65-48F9-8084-D011C03644F6</gtr:id><gtr:title>MSF Campaign for Access to Essential Medicines ? ART Sequencing Workshop</gtr:title><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/5f1d0b33a9155ad878eeb3bfd94192bb"><gtr:id>5f1d0b33a9155ad878eeb3bfd94192bb</gtr:id><gtr:otherNames>Steve  Rannard (Author)</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/00162C4E-B822-4C36-BB44-B9EF9BCBF9E4"><gtr:id>00162C4E-B822-4C36-BB44-B9EF9BCBF9E4</gtr:id><gtr:title>INVITED MRC/CDSS/RCUK Nanomedicine Workshop</gtr:title><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/379c8a6500a97b873ca17b2dc0a64cf2"><gtr:id>379c8a6500a97b873ca17b2dc0a64cf2</gtr:id><gtr:otherNames>Andrew Owen (Author)</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B36CDE49-2F63-4CF8-ADC4-1275F310EB0D"><gtr:id>B36CDE49-2F63-4CF8-ADC4-1275F310EB0D</gtr:id><gtr:title>Strengths, weaknesses, opportunities and challenges for long acting injectable therapies: Insights for applications in HIV therapy.</gtr:title><gtr:parentPublicationTitle>Advanced drug delivery reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/cf1d6d619c42388d8cdb238501bb7319"><gtr:id>cf1d6d619c42388d8cdb238501bb7319</gtr:id><gtr:otherNames>Owen A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0169-409X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/4C3FBC7C-0D5C-4FEF-92F2-4B1D3E21C46A"><gtr:id>4C3FBC7C-0D5C-4FEF-92F2-4B1D3E21C46A</gtr:id><gtr:title>The Application of Nanodispersions to Agriculture</gtr:title><gtr:parentPublicationTitle>Outlooks on Pest Management</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/91659901b152d665e5637cc8a03cef39"><gtr:id>91659901b152d665e5637cc8a03cef39</gtr:id><gtr:otherNames>Whitehouse P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/473189D6-26F7-4CE2-AD2A-41F6CA10E109"><gtr:id>473189D6-26F7-4CE2-AD2A-41F6CA10E109</gtr:id><gtr:title>Physiologically Based Pharmacokinetic Modelling to Inform Development of Intramuscular Long-Acting Nanoformulations for HIV.</gtr:title><gtr:parentPublicationTitle>Clinical pharmacokinetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e855f713559d0f11c6dc4c71c220ac34"><gtr:id>e855f713559d0f11c6dc4c71c220ac34</gtr:id><gtr:otherNames>Rajoli RK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0312-5963</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/31803B53-A19F-45BA-8E91-A5B8039E8750"><gtr:id>31803B53-A19F-45BA-8E91-A5B8039E8750</gtr:id><gtr:title>INVITED Nanomedicine Conference</gtr:title><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/41bbb57a2c373192de3711a2c22e3062"><gtr:id>41bbb57a2c373192de3711a2c22e3062</gtr:id><gtr:otherNames>Steven Rannard (Author)</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/70BA8C85-24FD-44DC-8595-98CF9F9B2BCF"><gtr:id>70BA8C85-24FD-44DC-8595-98CF9F9B2BCF</gtr:id><gtr:title>Nano4Life 2011</gtr:title><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/5f1d0b33a9155ad878eeb3bfd94192bb"><gtr:id>5f1d0b33a9155ad878eeb3bfd94192bb</gtr:id><gtr:otherNames>Steve  Rannard (Author)</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/69127587-248B-4B2E-B8C4-5D97BD8BAAA6"><gtr:id>69127587-248B-4B2E-B8C4-5D97BD8BAAA6</gtr:id><gtr:title>The application of nanotechnology in medicine: treatment and diagnostics.</gtr:title><gtr:parentPublicationTitle>Nanomedicine (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/cf1d6d619c42388d8cdb238501bb7319"><gtr:id>cf1d6d619c42388d8cdb238501bb7319</gtr:id><gtr:otherNames>Owen A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1743-5889</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/9C87752C-D840-4194-8105-187EC75E8FDA"><gtr:id>9C87752C-D840-4194-8105-187EC75E8FDA</gtr:id><gtr:title>Preparation and pH-responsive release of organic nanoparticles</gtr:title><gtr:parentPublicationTitle>JOURNAL OF PHARMACY AND PHARMACOLOGY</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b55475aabac8217142c10a26068a355c"><gtr:id>b55475aabac8217142c10a26068a355c</gtr:id><gtr:otherNames>Grant N.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-3573</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/8DE6ADBE-975F-4F73-8F1B-6ED55584BB49"><gtr:id>8DE6ADBE-975F-4F73-8F1B-6ED55584BB49</gtr:id><gtr:title>INVITED Armourers and Brasiers Forum</gtr:title><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/41bbb57a2c373192de3711a2c22e3062"><gtr:id>41bbb57a2c373192de3711a2c22e3062</gtr:id><gtr:otherNames>Steven Rannard (Author)</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C4906B85-8173-4AA4-BB80-44EF5D4C5A8D"><gtr:id>C4906B85-8173-4AA4-BB80-44EF5D4C5A8D</gtr:id><gtr:title>Towards a rational design of solid drug nanoparticles with optimised pharmacological properties.</gtr:title><gtr:parentPublicationTitle>Journal of interdisciplinary nanomedicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/65da67b16bc5ccd9ce1b330b734b99ed"><gtr:id>65da67b16bc5ccd9ce1b330b734b99ed</gtr:id><gtr:otherNames>Siccardi M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2058-3273</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A35BB1EE-6667-48AD-8E63-2AE5E82D3B6B"><gtr:id>A35BB1EE-6667-48AD-8E63-2AE5E82D3B6B</gtr:id><gtr:title>2nd Nanotoday Conference</gtr:title><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/5f1d0b33a9155ad878eeb3bfd94192bb"><gtr:id>5f1d0b33a9155ad878eeb3bfd94192bb</gtr:id><gtr:otherNames>Steve  Rannard (Author)</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/100BE413-B48B-4876-9FA3-AC80F892C2C0"><gtr:id>100BE413-B48B-4876-9FA3-AC80F892C2C0</gtr:id><gtr:title>Accelerated oral nanomedicine discovery from miniaturized screening to clinical production exemplified by paediatric HIV nanotherapies.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/236f8fefb1de42b371cef64a9fd83257"><gtr:id>236f8fefb1de42b371cef64a9fd83257</gtr:id><gtr:otherNames>Giardiello M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/3EE3E1FD-83A6-497E-9A9E-661257460BE9"><gtr:id>3EE3E1FD-83A6-497E-9A9E-661257460BE9</gtr:id><gtr:title>Reactions of hydrophobic organic nanoparticle mixtures in water: nanoparticle-on-nanoparticle oxidative dye bleaching</gtr:title><gtr:parentPublicationTitle>Green Chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/236f8fefb1de42b371cef64a9fd83257"><gtr:id>236f8fefb1de42b371cef64a9fd83257</gtr:id><gtr:otherNames>Giardiello M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/5D8B21BB-F049-4B17-A992-76E44A4DEB5F"><gtr:id>5D8B21BB-F049-4B17-A992-76E44A4DEB5F</gtr:id><gtr:title>In vitro characterization of efavirenz-containing solid drug nanoparticles</gtr:title><gtr:parentPublicationTitle>ANTIVIRAL THERAPY</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/151899c7dd6c7ddeaac6bd47d81d2efa"><gtr:id>151899c7dd6c7ddeaac6bd47d81d2efa</gtr:id><gtr:otherNames>King S. C.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1359-6535</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/90988619-D1EE-4A0A-9CAD-A27863EB29A4"><gtr:id>90988619-D1EE-4A0A-9CAD-A27863EB29A4</gtr:id><gtr:title>Nanomedicine: Not a case of &amp;quot;One size fits all&amp;quot;</gtr:title><gtr:parentPublicationTitle>Nano Today</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/32b55b6ffdb6345b72273d9268f5c791"><gtr:id>32b55b6ffdb6345b72273d9268f5c791</gtr:id><gtr:otherNames>Rannard S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/F27975E1-E199-4D09-8611-03D8183035D2"><gtr:id>F27975E1-E199-4D09-8611-03D8183035D2</gtr:id><gtr:title>Influence of particle size and surface charge on the cytotoxicity of nanodispersions</gtr:title><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/de646f57b0781b259edd791389b0bef3"><gtr:id>de646f57b0781b259edd791389b0bef3</gtr:id><gtr:otherNames>Darren Smith</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/8AB15957-DB6D-4A80-A771-F23DEC21D95D"><gtr:id>8AB15957-DB6D-4A80-A771-F23DEC21D95D</gtr:id><gtr:title>Rapid nanoformulation and GMP preparation of antiretroviral drugs for oral HIV nanomedicines and human clinical dosing studies</gtr:title><gtr:parentPublicationTitle>Converging technology for nanobio-applications of the E-MRS 2014 Spring Meeting</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/236f8fefb1de42b371cef64a9fd83257"><gtr:id>236f8fefb1de42b371cef64a9fd83257</gtr:id><gtr:otherNames>Giardiello M</gtr:otherNames></gtr:author></gtr:authors></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/76A31BFE-5F0F-477C-BA0E-2A8D446940A0"><gtr:id>76A31BFE-5F0F-477C-BA0E-2A8D446940A0</gtr:id><gtr:title>RSC 10th International Conference on Materials Chemistry</gtr:title><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f7042dbfbf2377a7f8f059a1226f8c65"><gtr:id>f7042dbfbf2377a7f8f059a1226f8c65</gtr:id><gtr:otherNames>Tom McDonald (Author)</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/DEA31E2E-BD6F-4F5E-A4AA-AB05F8D4D3A9"><gtr:id>DEA31E2E-BD6F-4F5E-A4AA-AB05F8D4D3A9</gtr:id><gtr:title>244th ACS National Meeting &amp;amp; Exposition</gtr:title><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/5f1d0b33a9155ad878eeb3bfd94192bb"><gtr:id>5f1d0b33a9155ad878eeb3bfd94192bb</gtr:id><gtr:otherNames>Steve  Rannard (Author)</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/F1C4DB42-E067-4271-808C-B96E83E040E6"><gtr:id>F1C4DB42-E067-4271-808C-B96E83E040E6</gtr:id><gtr:title>Influence of particle size and surface charge on the cytotoxicity of nanodispersions</gtr:title><gtr:parentPublicationTitle>DRUG METABOLISM REVIEWS</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ef77383a4642764590390e0546b22878"><gtr:id>ef77383a4642764590390e0546b22878</gtr:id><gtr:otherNames>Martin Phillip</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0360-2532</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/CAC9351F-0B09-4C00-A587-B5924E7482D1"><gtr:id>CAC9351F-0B09-4C00-A587-B5924E7482D1</gtr:id><gtr:title>The DAIDS Workshop: Nano &amp;amp; Emerging Technologies for HIV and the Second Annual Conference of the American Society for Nanomedicine</gtr:title><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/91e7fdbac79e2e16955c5bf004c271a8"><gtr:id>91e7fdbac79e2e16955c5bf004c271a8</gtr:id><gtr:otherNames>Andrew  Owen (Author)</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/272C0A3F-687F-456C-A744-933E3FA9F344"><gtr:id>272C0A3F-687F-456C-A744-933E3FA9F344</gtr:id><gtr:title>Beating HIV with a nanosized stick</gtr:title><gtr:parentPublicationTitle>Education in Chemistry -London-</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/c9160aacd1916e8ca6a9bbe0ac8e79e8"><gtr:id>c9160aacd1916e8ca6a9bbe0ac8e79e8</gtr:id><gtr:otherNames>Nina Notman (Author)</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E63335D3-B952-4AA5-B66C-E7961637F20F"><gtr:id>E63335D3-B952-4AA5-B66C-E7961637F20F</gtr:id><gtr:title>Partial mitigation of gold nanoparticle interactions with human lymphocytes by surface functionalization with a 'mixed matrix'.</gtr:title><gtr:parentPublicationTitle>Nanomedicine (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/936be8fe289660558eed2b8dc4f61ee3"><gtr:id>936be8fe289660558eed2b8dc4f61ee3</gtr:id><gtr:otherNames>Liptrott NJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1743-5889</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/5FA2D021-B17B-4152-B28E-0AD2501258B3"><gtr:id>5FA2D021-B17B-4152-B28E-0AD2501258B3</gtr:id><gtr:title>Rapid &amp;quot;bottom-up&amp;quot; production of organic nanoparticles: From drug bioavailability enhancement to fluorescence studies of cellular accumulation</gtr:title><gtr:parentPublicationTitle>ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/c531d7d54969cfc0ee4ded59357058a8"><gtr:id>c531d7d54969cfc0ee4ded59357058a8</gtr:id><gtr:otherNames>Rannard Steve P.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0065-7727</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D824532B-41B2-4C99-8DBB-D29B4A8B91F3"><gtr:id>D824532B-41B2-4C99-8DBB-D29B4A8B91F3</gtr:id><gtr:title>Nanoengineering</gtr:title><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/722518fc75cb6d2dd93af953554f8a4f"><gtr:id>722518fc75cb6d2dd93af953554f8a4f</gtr:id><gtr:otherNames>McDonald T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:isbn>9780444627476</gtr:isbn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/4A4AAC39-9C95-4BFD-BAD7-D3861964226D"><gtr:id>4A4AAC39-9C95-4BFD-BAD7-D3861964226D</gtr:id><gtr:title>Multicomponent Organic Nanoparticles for Fluorescence Studies in Biological Systems</gtr:title><gtr:parentPublicationTitle>Advanced Functional Materials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/722518fc75cb6d2dd93af953554f8a4f"><gtr:id>722518fc75cb6d2dd93af953554f8a4f</gtr:id><gtr:otherNames>McDonald T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/AD825D98-DFD1-40AA-A502-D58E51D1FE67"><gtr:id>AD825D98-DFD1-40AA-A502-D58E51D1FE67</gtr:id><gtr:title>INVITED presentation at Formula VI</gtr:title><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/41bbb57a2c373192de3711a2c22e3062"><gtr:id>41bbb57a2c373192de3711a2c22e3062</gtr:id><gtr:otherNames>Steven Rannard (Author)</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/68E68651-3338-483D-A762-7F4F7C8A6662"><gtr:id>68E68651-3338-483D-A762-7F4F7C8A6662</gtr:id><gtr:title>INVITED British HIV Association</gtr:title><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/41bbb57a2c373192de3711a2c22e3062"><gtr:id>41bbb57a2c373192de3711a2c22e3062</gtr:id><gtr:otherNames>Steven Rannard (Author)</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/26923A75-42FE-4CE6-90A9-0DE41B2D2271"><gtr:id>26923A75-42FE-4CE6-90A9-0DE41B2D2271</gtr:id><gtr:title>Secrets of Formulation III</gtr:title><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/5f1d0b33a9155ad878eeb3bfd94192bb"><gtr:id>5f1d0b33a9155ad878eeb3bfd94192bb</gtr:id><gtr:otherNames>Steve  Rannard (Author)</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/0013A8A3-FC9D-4FB9-893B-504A4FAE63DB"><gtr:id>0013A8A3-FC9D-4FB9-893B-504A4FAE63DB</gtr:id><gtr:title>Rapid &amp;quot;bottom-up&amp;quot; production of organic nanoparticles: From drug bioavailability enhancement to fluorescence studies of cellular accumulation</gtr:title><gtr:parentPublicationTitle>ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/c531d7d54969cfc0ee4ded59357058a8"><gtr:id>c531d7d54969cfc0ee4ded59357058a8</gtr:id><gtr:otherNames>Rannard Steve P.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0065-7727</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/4D86FC3D-E213-4D99-B7B3-F673CF78CC76"><gtr:id>4D86FC3D-E213-4D99-B7B3-F673CF78CC76</gtr:id><gtr:title>International Society for the Study of Xenobiotics</gtr:title><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/091f181762f4b6c4016a7e6c2d1dd5f3"><gtr:id>091f181762f4b6c4016a7e6c2d1dd5f3</gtr:id><gtr:otherNames>Phillip Martin (Author)</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/0CDD3051-BEFA-41FB-9ECA-3D2641C9638E"><gtr:id>0CDD3051-BEFA-41FB-9ECA-3D2641C9638E</gtr:id><gtr:title>High-throughput nanoprecipitation of the organic antimicrobial triclosan and enhancement of activity against Escherichia coli</gtr:title><gtr:parentPublicationTitle>Journal of Materials Chemistry B</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/722518fc75cb6d2dd93af953554f8a4f"><gtr:id>722518fc75cb6d2dd93af953554f8a4f</gtr:id><gtr:otherNames>McDonald T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7D60D231-7225-4193-AF12-A39E4F8FFCA4"><gtr:id>7D60D231-7225-4193-AF12-A39E4F8FFCA4</gtr:id><gtr:title>3rd Annual World Drug Delivery &amp;amp; Formulation Summit</gtr:title><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/5f1d0b33a9155ad878eeb3bfd94192bb"><gtr:id>5f1d0b33a9155ad878eeb3bfd94192bb</gtr:id><gtr:otherNames>Steve  Rannard (Author)</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/04D9D7A0-1FCF-486F-A628-A77A5E829F75"><gtr:id>04D9D7A0-1FCF-486F-A628-A77A5E829F75</gtr:id><gtr:title>Augmented Inhibition of CYP3A4 in Human Primary Hepatocytes by Ritonavir Solid Drug Nanoparticles.</gtr:title><gtr:parentPublicationTitle>Molecular pharmaceutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/8aebd9fcdb75ba6a10430e6f39a62dd8"><gtr:id>8aebd9fcdb75ba6a10430e6f39a62dd8</gtr:id><gtr:otherNames>Martin P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1543-8384</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D20F683B-77D6-4C69-B6DB-905DA13A70B2"><gtr:id>D20F683B-77D6-4C69-B6DB-905DA13A70B2</gtr:id><gtr:title>Influence of particle size and surface charge on the cytotoxicity of nanodispersions</gtr:title><gtr:parentPublicationTitle>DRUG METABOLISM REVIEWS</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ef77383a4642764590390e0546b22878"><gtr:id>ef77383a4642764590390e0546b22878</gtr:id><gtr:otherNames>Martin Phillip</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0360-2532</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/84D98393-3CB9-42A0-8EE4-C306424C2339"><gtr:id>84D98393-3CB9-42A0-8EE4-C306424C2339</gtr:id><gtr:title>INVITED: Improved Oral Delivery of Antiretroviral Drugs Via A Novel Synthesis of Solid Drug Nanoparticle Formulations</gtr:title><gtr:parentPublicationTitle>Nanomedicine 2014</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/cf1d6d619c42388d8cdb238501bb7319"><gtr:id>cf1d6d619c42388d8cdb238501bb7319</gtr:id><gtr:otherNames>Owen A</gtr:otherNames></gtr:author></gtr:authors></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A9C478A2-72FC-441B-8CC5-688184F358E7"><gtr:id>A9C478A2-72FC-441B-8CC5-688184F358E7</gtr:id><gtr:title>MRS Spring Meeting 2011</gtr:title><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d895d14ee61ac81f19295ea64e2aff6a"><gtr:id>d895d14ee61ac81f19295ea64e2aff6a</gtr:id><gtr:otherNames>Marco Giardiello (Author)</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/0CF8DFE3-60E1-478A-A98B-4A241F8B60E4"><gtr:id>0CF8DFE3-60E1-478A-A98B-4A241F8B60E4</gtr:id><gtr:title>POLY 529-Water-dispersible organic nanoparticles by freeze drying</gtr:title><gtr:parentPublicationTitle>ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/edf9cce415f1259ec0078ac2ebeeffad"><gtr:id>edf9cce415f1259ec0078ac2ebeeffad</gtr:id><gtr:otherNames>Zhang Haifei</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0065-7727</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A7A60595-9F76-4EF8-8DE9-C5CE13C881CB"><gtr:id>A7A60595-9F76-4EF8-8DE9-C5CE13C881CB</gtr:id><gtr:title>18th Conference on Retroviruses and Opportunistic Infections</gtr:title><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9b4cf9ee90c62c1b9e3b44dce688399f"><gtr:id>9b4cf9ee90c62c1b9e3b44dce688399f</gtr:id><gtr:otherNames>Darren Smith (Author)</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/3C5A6D6D-42B9-47A7-B055-2197C4EB15C4"><gtr:id>3C5A6D6D-42B9-47A7-B055-2197C4EB15C4</gtr:id><gtr:title>&amp;quot;Rapid &amp;quot;&amp;quot;bottom-up&amp;quot;&amp;quot; production of organic nanoparticles: From drug bioavailability enhancement to fluorescence studies of cellular accumulation&amp;quot;</gtr:title><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e70cb32bd30566135ed3c1a9049031cc"><gtr:id>e70cb32bd30566135ed3c1a9049031cc</gtr:id><gtr:otherNames>Marco Giardiello</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/8C87DB9E-35ED-4301-A7D9-D7FE328C2395"><gtr:id>8C87DB9E-35ED-4301-A7D9-D7FE328C2395</gtr:id><gtr:title>Mediation of in vitro cytochrome p450 activity by common pharmaceutical excipients.</gtr:title><gtr:parentPublicationTitle>Molecular pharmaceutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/8aebd9fcdb75ba6a10430e6f39a62dd8"><gtr:id>8aebd9fcdb75ba6a10430e6f39a62dd8</gtr:id><gtr:otherNames>Martin P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1543-8384</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">EP/G066272/1</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects><gtr:researchSubject><gtr:id>6723A70B-A523-40AB-9740-B6AD2A0677B7</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Medical &amp; health interface</gtr:text></gtr:researchSubject></gtr:researchSubjects><gtr:researchTopics><gtr:researchTopic><gtr:id>B30DC286-3309-48E2-A15D-BDF547057A33</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Drug Formulation &amp; Delivery</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>